Still life of Ozempic and Wegovy. Both are injectable prescription weight loss medicines. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) As demand surges for semaglutide ...
Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs exclusively. Compounding is the practice of ...
Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...
The US Food and Drug Administration’s (FDA) has called on its Pharmacy Compounding Advisory Committee to discuss whether a dozen peptide drugs should be eligible for compounding by licensed facilities ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. Copycat medications, produced through a ...
Empower Pharmacy markets itself as a well-meaning rival to Big Pharma — one that seeks to democratize medicine by making affordable, personalized drugs for patients who need them. As one of an ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests there is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results